- Report
- February 2026
- 250 Pages
Global
From €4038EUR$4,490USD£3,482GBP
- Report
- December 2025
- 200 Pages
Global
From €2689EUR$2,990USD£2,319GBP
- Report
- March 2026
- 485 Pages
Global
From €5261EUR$5,850USD£4,537GBP
- Report
- March 2026
- 483 Pages
Global
From €5261EUR$5,850USD£4,537GBP
- Report
- March 2026
- 377 Pages
Global
From €5261EUR$5,850USD£4,537GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1124EUR$1,250USD£969GBP
- Report
- February 2026
- 250 Pages
Global
From €4038EUR$4,490USD£3,482GBP
- Report
- January 2026
- 186 Pages
Global
From €4047EUR$4,500USD£3,490GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €2248EUR$2,500USD£1,939GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2508EUR$2,789USD£2,163GBP
- Report
- March 2025
- 150 Pages
Global
From €3462EUR$3,850USD£2,986GBP
€4361EUR$4,850USD£3,762GBP
- Report
- November 2025
- 196 Pages
Global
From €4451EUR$4,950USD£3,839GBP
- Report
- June 2025
- 200 Pages
United States
From €2239EUR$2,490USD£1,931GBP
- Report
- August 2022
- 115 Pages
Global
From €4047EUR$4,500USD£3,490GBP
- Report
- August 2024
- 233 Pages
Global
From €7149EUR$7,950USD£6,166GBP
- Report
- June 2024
- 185 Pages
Global
From €4047EUR$4,500USD£3,490GBP
- Report
- January 2024
- 395 Pages
Global
From €6745EUR$7,500USD£5,817GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2508EUR$2,789USD£2,163GBP
- Report
- May 2024
- 132 Pages
Global
From €3596EUR$3,999USD£3,102GBP
- Report
- May 2024
- 138 Pages
Global
From €3596EUR$3,999USD£3,102GBP

Epidiolex is a pharmaceutical drug used to treat certain types of epilepsy. It is the first FDA-approved drug derived from cannabidiol (CBD), a component of the cannabis plant. Epidiolex is used to treat two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is classified as a central nervous system (CNS) drug, which are drugs that act on the brain and spinal cord to treat neurological disorders.
Epidiolex is manufactured by GW Pharmaceuticals, a British biopharmaceutical company. It is distributed in the United States by Greenwich Biosciences, a subsidiary of GW Pharmaceuticals. Other companies in the CNS drug market include AbbVie, Allergan, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more